ACR updates advice on reducing the risk of steroid-induced osteoporosis

On September 14, 2022, the American College of Rheumatology (ACR) released a summary of Updated guidelines (PDF) on how to manage glucocorticoid-induced osteoporosis (GIOP), a condition that can occur in people who take steroids as part of their treatment. The full manuscript is expected to be released in 2023.

The update comes five years after the 2017 ACR recommendations and includes information on the newer osteoporosis treatments, Tymlos (abaloparatide) and Evenity (romosozumab), as well as recommendations for sequential therapy to prevent rebound fractures.

Steroids relieve symptoms and treat many conditions, but they may increase the risk of osteoporosis

Glucocorticoids (GCs) can reduce inflammation and pain common in rheumatic diseases such as Rheumatoid arthritis (RA) In addition to other chronic conditions, including multiple sclerosis (MS), Crohn’s disease, and ulcerative colitis (University of California), psoriasis, skin diseaseAllergies, asthma and heart failure.

Related: 8 great pain relievers you don’t use